Loracarbef (LY163892) in the treatment of acute exacerbations of chronic bronchitis: Results of U.S. and European comparative clinical trials
- 22 June 1992
- journal article
- clinical trial
- Published by Elsevier in The American Journal of Medicine
- Vol. 92 (6) , S58-S64
- https://doi.org/10.1016/0002-9343(92)90609-f
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- In-vitro activity of cefprozil (BMY 28100) and loracarbef (LY 163892) against pathogens obtained from middle ear fluidJournal of Antimicrobial Chemotherapy, 1991
- Comparative in vitro activities of several new fluoroquinolones and beta-lactam antimicrobial agents against community isolates of Streptococcus pneumoniaeAntimicrobial Agents and Chemotherapy, 1990
- Critical assessment of the newer non-quinolone oral antimicrobial agentsAntimicrobic Newsletter, 1989
- In vitro and in vivo antibacterial activity of KT3777, a new orally active carbacephem.The Journal of Antibiotics, 1989
- Comparative in-vitro activity of a new oral carbacephem, LV163892Journal of Antimicrobial Chemotherapy, 1988
- Antimicrobial activity of LY163892, an orally administered 1-carbacephemJournal of Antimicrobial Chemotherapy, 1988
- In vitro activity and beta-lactamase stability of LY163892European Journal of Clinical Microbiology & Infectious Diseases, 1988
- In-vitro activity and β-lactamase stability of LY163892Journal of Antimicrobial Chemotherapy, 1988
- In vitro susceptibilities of common pediatric pathogens to LY163892Antimicrobial Agents and Chemotherapy, 1988
- In vitro activities of LY163892, cefaclor, and cefuroximeAntimicrobial Agents and Chemotherapy, 1988